NCT00047177View on ClinicalTrials.gov

Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

August 31, 2004

Study Completion Date

July 31, 2007

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

Oxaliplatin

Trial Locations (10)

15213

Children's Hospital of Pittsburgh, Pittsburgh

27710

Duke Comprehensive Cancer Center, Durham

60614

Children's Memorial Hospital - Chicago, Chicago

94115

UCSF Comprehensive Cancer Center, San Francisco

98105

Children's Hospital and Regional Medical Center - Seattle, Seattle

20010-2970

Children's National Medical Center, Washington D.C.

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

19104-4318

Children's Hospital of Philadelphia, Philadelphia

38105-2794

St. Jude Children's Research Hospital, Memphis

77030-2399

Texas Children's Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Pediatric Brain Tumor Consortium

NETWORK

NCT00047177 - Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor | Biotech Hunter | Biotech Hunter